Shearman & Sterling represented BofA Securities, Inc., Citigroup Global Markets Inc., Goldman Sachs & Co. LLC and Morgan Stanley & Co. LLC as joint book-running managers and representatives of the underwriters in connection with Amgen’s registered $4 billion notes offering, consisting of an additional $1 billion of its existing 2.200 percent senior notes due 2027, $1.25 billion of its 2.300 percent of senior notes due 2031, an additional $750 million of its existing 3.150 percent senior notes due 2040 and an additional $1 billion of its existing 3.375 percent senior notes due 2050.

Amgen is a global biotechnology company that discovers, develops, manufactures and delivers human therapeutics based on advances in cellular and molecular biology.

The Team